To include your compound in the COVID-19 Resource Center, submit it here.

Astellas, Pfizer discontinuing Xtandi for breast cancer

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) said they discontinued their development program for Xtandi enzalutamide to treat breast cancer. The oral androgen receptor (AR) antagonist is approved to treat

Read the full 318 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE